MedPath

Timolol

Generic Name
Timolol
Brand Names
Azarga, Betimol, Combigan, Cosopt, Duotrav, Istalol, Timoptic, Xalacom
Drug Type
Small Molecule
Chemical Formula
C13H24N4O3S
CAS Number
26839-75-8
Unique Ingredient Identifier
5JKY92S7BR
Background

Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.

Indication

Ophthalmic timolol is indicated for the treatment of increased intraocular pressure in patients with ocular hypertension or open-angle glaucoma. The oral form of this drug is used to treat high blood pressure. In certain cases, timolol is used in the prevention of migraine headaches.

Associated Conditions
Increased Intra Ocular Pressure (IOP), Migraine, Ocular Hypertension, Open Angle Glaucoma (OAG)
Associated Therapies
-
Clinical Trials
Related News

Pupillary Response After Glaucoma Medication

Not Applicable
Completed
Conditions
Drug Effect (Glaucoma Drugs)
Interventions
Drug: Latanoprost
Drug: Timolol
Drug: Dorzolamide
First Posted Date
2015-08-13
Last Posted Date
2015-08-13
Lead Sponsor
Glostrup University Hospital, Copenhagen
Target Recruit Count
21
Registration Number
NCT02522039
Locations
🇩🇰

Glostrup University Hospital, Glostrup, Denmark

Topical Timolol Benefit in Venous Ulcers

Phase 2
Completed
Conditions
Venous Leg Ulcers
Interventions
Drug: Timolol
Other: Local care treatment
First Posted Date
2015-04-21
Last Posted Date
2018-08-03
Lead Sponsor
Centre Hospitalier Universitaire, Amiens
Target Recruit Count
42
Registration Number
NCT02422017
Locations
🇫🇷

CHU Amiens, Amiens, France

Stop Retinal Ganglion Cell Dysfunction Study

First Posted Date
2015-03-17
Last Posted Date
2024-10-10
Lead Sponsor
University of Miami
Target Recruit Count
500
Registration Number
NCT02390284
Locations
🇺🇸

Bascom Palmer Eye Institute - University of Miami, Miami, Florida, United States

Phase 2b Study Evaluating Safety and Efficacy of OTX-TP Compared to Timolol Drops in the Treatment of Subjects With Open Angle Glaucoma or Ocular Hypertension

Phase 2
Completed
Conditions
Ocular Hypertension
Glaucoma
Interventions
Drug: OTX-TP
Drug: Timolol
First Posted Date
2014-12-09
Last Posted Date
2016-12-14
Lead Sponsor
Ocular Therapeutix, Inc.
Target Recruit Count
72
Registration Number
NCT02312544
Locations
🇺🇸

Vold Vision, Fayetteville, Arkansas, United States

The Effect of Topical Treatment With Combigan Compared to Timolol and Brimonidine on Pupil Diameter

First Posted Date
2014-08-12
Last Posted Date
2015-10-14
Lead Sponsor
Carmel Medical Center
Target Recruit Count
25
Registration Number
NCT02214680
Locations
🇮🇱

Carmel Medical Center, Haifa, Israel

Effect of Antiglaucoma Agents on Short Term Intraocular Pressure Fluctuations After Intravitreal Bevacizumab Injection

Not Applicable
Completed
Conditions
Intraocular Pressure Change in Intravitreal Injection
Interventions
Drug: Timolol
Drug: Brimonidine
Drug: Acetazolamide
Drug: Mannitol
Drug: Placebo
First Posted Date
2014-05-16
Last Posted Date
2014-05-16
Lead Sponsor
Mashhad University of Medical Sciences
Target Recruit Count
70
Registration Number
NCT02140450
Locations
🇮🇷

Retina Research Center, Khatam eye Hospital, Mashhad, Khorasan Razavi, Iran, Islamic Republic of

The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients.

Phase 4
Withdrawn
Conditions
Glaucoma
Ocular Hypertension
Thyroid Eye Disease
Interventions
Drug: Prostaglandin Analog
Drug: Timolol
First Posted Date
2013-08-22
Last Posted Date
2018-05-15
Lead Sponsor
Stanford University
Registration Number
NCT01927406
Locations
🇺🇸

Stanford Hospital and Clinics, Stanford, California, United States

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

Phase 2
Completed
Conditions
Primary Open-Angle Glaucoma (POAG)
Ocular Hypertension (OHT)
Interventions
Drug: Trabodenoson
Drug: Latanoprost
Drug: Timolol
First Posted Date
2013-08-06
Last Posted Date
2017-12-02
Lead Sponsor
Inotek Pharmaceuticals Corporation
Target Recruit Count
101
Registration Number
NCT01917383
Locations
🇺🇸

Chiltern, Bristol, Tennessee, United States

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 3
Completed
Conditions
Open-Angle Glaucoma
Ocular Hypertension
Interventions
Drug: BOL-303259-X
Drug: Timolol
First Posted Date
2012-12-17
Last Posted Date
2018-11-21
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
420
Registration Number
NCT01749930
Locations
🇺🇸

Bausch & Lomb Inc., Rochester, New York, United States

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Phase 3
Completed
Conditions
Open-Angle Glaucoma
Ocular Hypertension
Interventions
Drug: BOL-303259-X
Drug: Timolol
First Posted Date
2012-12-17
Last Posted Date
2018-11-07
Lead Sponsor
Bausch & Lomb Incorporated
Target Recruit Count
420
Registration Number
NCT01749904
Locations
🇺🇸

Bausch & Lomb Inc., Rochester, New York, United States

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy